Analysts/Institutional Investor Meet/Con. Call Updates

November 03, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Madam, Sub: Transcript of the Q2 FY '27 Results Conference Call hosted on October 29, 2026 Pursuant to Regulation 30 & 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to our results conference call intimation dated October 13, 2026, please be informed that the results conference call for Q2 FY27 was hosted on October 29, 2026 and the transcript of the conference call is enclosed herewith. This is for your information and records. Thanking You. Yours faithfully, For Laurus Labs Limited G. Venkateswar Reddy Company Secretary & Compliance Officer Encl: A/a “Laurus Labs Limited Q2 FY27 Earnings Conference Call” October 29, 2026 MANAGEMENT: DR. SATYANARAYANA CHAVA – FOUNDER AND CHIEF EXECUTIVE OFFICER – LAURUS LABS LIMITED MR. V. V. RAVI KUMAR – EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER – LAURUS LABS LIMITED MR. KRISHNA CHAITANYA CHAVA – EXECUTIVE DIRECTOR, HEAD CDMO – LAURUS LABS LIMITED MRS. SOUMYA CHAVA – EXECUTIVE DIRECTOR AFFORDABLE MEDICINES AND COMMERCIAL – LAURUS LABS LIMITED MR. VIVEK KUMAR – ASSISTANT VICE PRESIDENT – INVESTOR RELATIONS – LAURUS LABS LIMITED MODERATOR: MR. NITIN AGARWAL – DAM CAPITAL ADVISORS LIMITED Page 1 of 20 Laurus Labs Limited October 29, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Laurus Labs Q2 FY27 Earnings Conference Call hosted by DAM Capital Ltd. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Nitin Agarwal from DAM Capital Advisors Limited. Please go ahead, sir. Nitin Agarwal: Thank you. Good afternoon, everyone, and a very warm welcome to Laurus Labs Q2 FY27 Earnings Call hosted by DAM Capital Advisors Limited. On the call today, we have representing Laurus Labs management are, Dr. Satyanarayana Chava, Founder and CEO; Mr. V. V. Ravi Kumar, Executive Director and CFO; Mr. Krishna Chaitanya Chava, ED, Head CDMO; Mrs. Soumya Chava, ED, Affordable Medicines and Commercial; and Mr. Vivek Kumar, AVP, Investor Relations. Before we proceed, I would like to remind you that some of the statements made during the call today could be forward-looking in nature, and a safe harbor statement to this effect has been included in the press release that has been shared on the company's website. I hand over the call to Dr. Chava to make the opening comments, and then we'll open the floor for questions. Please go ahead, sir. Satyanarayana Chava: Thanks, Nitin. Good afternoon to all our stakeholders. We are pleased with the substantial progress company making across various business segments. We continue to report strong growth in CDMO business, steady momentum in affordable medicine portfolio because of our major advancement in our partners' clinical and commercial programs. The strong performance reflects sustainable robust demand for our specialized capabilities, integrated offerings, depth of our customer relationships and disciplined operational execution by our team. In line with our accelerating transformation strategy, we are actively investing into building scientific capabilities and capacities across complex and new modalities. The company's total reactor volume for small molecules API in operation has now reached over 9,000 kiloliters, and we will continue to expand further. We are also pleased to highlight some of the important disclosures we have made in this quarter's investor presentation on the advancements we are making in our integrated peptide CDMO capability. We commissioned commercial-scale peptide manufacturing block. Our current reactor volume for solid-phase peptide synthesis is over 16,000 liters, and we have taken up a significant further expansions to meet diverse program requirements. We continue to strengthen the capacity of liquid-phase peptide synthesis and several new technologies. We are also augmenting our capacity through disciplined business development. During the quarter, we have announced investment into 2 technology platform companies. The one is an Page 2 of 20 Laurus Labs Limited October 29, 2026 agreement to acquire majority 60% stake in Canada-based Galenvs Sciences, specializing in oligonucleotides and precision magnetic nanoparticles-based purification. By leveraging Galenvs's expertise in early-stage oligo projects, process development, conjugation, advance purification and fill finish, along with Laurus's large-scale expertise in complex chemistry, we intend to support clients with seamless journey from complex RNA DNA-based therapies as a one-stop solution. Together, this will expand Laurus's position to participate in emerging high-growth oligo market. Second is an acquisition of majority stake in SI & C Resins, a peptide resin technology-focused company based out of Hyderabad. This will allow us to enhance long-term supply security by in-sourcing critical solid support resins for peptide synthesis and also chromatography stationary phases for large-scale peptide purification. This will bolster Laurus's manufacturing competitiveness and reliability with our current and future partners' programs. These acquisitions are aimed to advance Laurus's integrated scientific capabilities under one roof. These acquisitions are strengthened by Laurus's quality infrastructure that will cater to more complex customized projects, along with significant increase in future therapeutic demands. Moving on to our financial results. Laurus has maintained its growth trajectory and once again delivered a record revenue and profits for quarter 2. Total revenues were INR2,206 crores, reflecting a continued strength of our CDMO platform, growing contribution from commercial- based supplies and ongoing momentum in Affordable medicines portfolio. Gross margins were also healthy and maintained at around 63%, and EBITDA margins further expanded over previous quarters by 2.7 percentage points to 34.5%. Our product mix and operating leverage continue to do well, supporting healthy margins overall. I would request Mr. Krishna Chaitanya to share key updates on our CDMO business. Krishna Chava: Thank you. Coming to the small molecule CDMO, the business has continued to deliver robust operational execution in Q2, reporting an 86% growth with the sales of INR875 crores. For the first half of the current financial year, the division recorded INR1,710 crores. That equates to about 77% growth. This performance was driven by successful delivery of critical late-stage programs as well as commercial API supplies to multiple global partners. We also continue to see encouraging demand on the newly commissioned assets across both Human Health and Animal Health businesses, both in terms of the volumes and opportunities with existing partners as well as with new client engagements. The company remains focused on enhancing our core capabilities and capacities to better meet customer demand driven by continuous expansions. As Dr. Satya highlighted in the opening Page 3 of 20 Laurus Labs Limited October 29, 2026 remarks, we have commissioned our peptide manufacturing facility and our investment towards other multiple large-scale API opportunities continues to take place in our Vizag site. Strategically, we are elevating client collaboration on complex new modalities and our focus remains on securing fully integrated projects, seamlessly supporting partners from preclinical development going all the way to finished drug product service [Showing first 8,000 characters — download PDF for full document]